This will help inform the combination use of FDA-approved MEK inhibitors and STAT3 inhibitor in an ongoing phase I clinical trials (ClinicalTrials.gov ID:NCT03195699) to treat with KRAS-mutant lung cancer bone metastasis patients. Here, STAT3 is linked to lung carcinoma.